NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.
Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.
A new analysis of a phase III trial of patients with neuroendocrine tumors that began in the gastrointestinal (GI) tract or at an unknown primary location found that progression-free survival was improved with everolimus by 6 to 8 months compared with placebo.
Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs.
Greater benefit with temozolomide, bevacizumab for patients with pancreatic versus carcinoid NETs.
Perioperative chemotherapy may benefit persons with resected small-cell lung cancer (SCLC) or large-cell neuroendocrine carcinomas (LCNECs).
Progression-free survival improved in patients with advanced neuroendocrine tumors when everolimus rather than placebo was used in combination with octreotide long-acting repeatable.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|